Business Description
Vaxart Inc
NAICS : 325414
SIC : 2836
ISIN : US92243A2006
Total Employee Number:
65Description
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.66 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.17 | |||||
Interest Coverage | 16.38 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -0.11 | |||||
Beneish M-Score | 1.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 909.9 | |||||
3-Year Book Growth Rate | -23.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -72.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.71 | |||||
Quick Ratio | 1.71 | |||||
Cash Ratio | 0.79 | |||||
Days Sales Outstanding | 20.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 | |||||
Shareholder Yield % | 4.38 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 14.94 | |||||
Net Margin % | 14.51 | |||||
EBITDA Margin % | 18.5 | |||||
FCF Margin % | 5.66 | |||||
OCF Margin % | 5.84 | |||||
ROE % | 64.59 | |||||
ROA % | 20.66 | |||||
ROIC % | 29.28 | |||||
3-Year ROIIC % | 1312.02 | |||||
ROC (Joel Greenblatt) % | 185.06 | |||||
ROCE % | 57.16 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.6 | |||||
Forward PE Ratio | 1.42 | |||||
PE Ratio without NRI | 3.6 | |||||
Price-to-Owner-Earnings | 24.55 | |||||
PS Ratio | 0.49 | |||||
PB Ratio | 1.38 | |||||
Price-to-Tangible-Book | 1.52 | |||||
Price-to-Free-Cash-Flow | 8.71 | |||||
Price-to-Operating-Cash-Flow | 8.57 | |||||
EV-to-EBIT | 1.95 | |||||
EV-to-EBITDA | 1.64 | |||||
EV-to-Revenue | 0.3 | |||||
EV-to-Forward-Revenue | 9.68 | |||||
EV-to-FCF | 5.25 | |||||
Price-to-Median-PS-Value | 0.09 | |||||
Price-to-Graham-Number | 0.49 | |||||
| Price-to-Net-Current-Asset-Value | 2.92 | |||||
Earnings Yield (Greenblatt) % | 51.28 | |||||
FCF Yield % | 11.32 | |||||
Forward Rate of Return (Yacktman) % | -2725.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaxart Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 219.093 | ||
| EPS (TTM) (€) | 0.11 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.26 | ||
| Volatility % | 9 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 0.38 | ||
| 12-1 Month Momentum % | 1.6 | ||
| 52-Week Range (€) | 0.2576 - 0.642 | ||
| Shares Outstanding (Mil) | 241.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaxart Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaxart Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 103 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 102 days | ||
| Vaxart Stockholder Fireside Chat | 2026-08-07 16:30 | In 5 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 | In 3 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 3 days | ||
| Guidance call for 2026 | 2026-07-28 | 0.38 (+0.00%) | ||
| General meeting for 2026 | 2026-07-16 | 0.38 (+0.00%) | ||
| Vaxart, Inc Fireside Chat | 2026-05-08 16:30 | 0.38 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 0.38 (+0.00%) | ||
| Vaxart, Inc. Stockholder Fireside Chat | 2026-03-13 16:30 | 0.38 (+0.00%) |
Show
Entries
Vaxart Inc Frequently Asked Questions
What is Vaxart Inc(FRA:NB11)'s stock price today?
The current price of FRA:NB11 is €0.38. The 52 week high of FRA:NB11 is €0.64 and 52 week low is €0.26.
When is next earnings date of Vaxart Inc(FRA:NB11)?
The next earnings date of Vaxart Inc(FRA:NB11) is 2026-08-06.
Does Vaxart Inc(FRA:NB11) pay dividends? If so, how much?
Vaxart Inc(FRA:NB11) does not pay dividend.
Press Release
Articles on Vaxart Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers